Genagon Therapeutics drug development is based on the discovery of an unstudied protein and its life cycle in innate immune cells. Genagon was founded in 2015 and is building a strong and broad patent portfolio with opportunities for internal development and future partnerships. The company is supported financially by among others, Beijer Ventures, UU Invest, Almi Invest and Business angels.
Genagon provides the next generation of cancer treatment and will continue to fight cancer with the ambition to some day treat all cancers. The next generation of cancer treatment gives todays untreatable patients a new chance for increased quality of life and remission and eventually even a become cancer-free.
Genagon develops the next generation of therapeutical ADCs with a unique target profile and the ability to treat solid tumors, where no successful standard of care treatment is available. Our pipeline focuses on a therapeutically novel class of transmembrane proteins accumulating on the surface of cancer cells and tumor promoting cells within the tumor microenvironment.